Abstract
Curcumin, a polyphenolic compound derived from the dietary spice turmeric, possesses diverse pharmacologic effects including anti-inflammatory, anti-oxidant, anti-proliferative and anti-angiogenic activities. Accumulating experimental evidence suggests that curcumin interferes with a variety of molecular targets and processes involved in cancer. Further, data obtained in multiple preclinical models, as well as in preliminary clinical trials, have documented minimal toxicity of curcumin, even at relatively high doses. However, the clinical advancement of this promising molecule has been hindered by its poor water solubility, short biological half-life, and low bioavailability after oral administration. A variety of approaches are being pursued to overcome these limitations, which include synthesis of curcumin analogues, the use of adjuvants (e.g. piperine), and the development of improved delivery platforms for the parental compound, including liposomal, nanoparticulated and phospholipid complex formulations of curcumin. This review is intended to provide the reader an update on the bioavailability and pharmacokinetic pitfalls of free curcumin, and a comprehensive cataloging of ongoing approaches that have been undertaken to resolve these issues, with the goal of harnessing the true potential of this anti-cancer agent in the clinical arena.
Keywords: Curcumin, polymeric nanoparticle, nanocurcumin, cancer, bioavailability
Current Drug Discovery Technologies
Title: Systemic Delivery of Curcumin: 21st Century Solutions for an Ancient Conundrum
Volume: 6 Issue: 3
Author(s): Savita Bisht and Anirban Maitra
Affiliation:
Keywords: Curcumin, polymeric nanoparticle, nanocurcumin, cancer, bioavailability
Abstract: Curcumin, a polyphenolic compound derived from the dietary spice turmeric, possesses diverse pharmacologic effects including anti-inflammatory, anti-oxidant, anti-proliferative and anti-angiogenic activities. Accumulating experimental evidence suggests that curcumin interferes with a variety of molecular targets and processes involved in cancer. Further, data obtained in multiple preclinical models, as well as in preliminary clinical trials, have documented minimal toxicity of curcumin, even at relatively high doses. However, the clinical advancement of this promising molecule has been hindered by its poor water solubility, short biological half-life, and low bioavailability after oral administration. A variety of approaches are being pursued to overcome these limitations, which include synthesis of curcumin analogues, the use of adjuvants (e.g. piperine), and the development of improved delivery platforms for the parental compound, including liposomal, nanoparticulated and phospholipid complex formulations of curcumin. This review is intended to provide the reader an update on the bioavailability and pharmacokinetic pitfalls of free curcumin, and a comprehensive cataloging of ongoing approaches that have been undertaken to resolve these issues, with the goal of harnessing the true potential of this anti-cancer agent in the clinical arena.
Export Options
About this article
Cite this article as:
Bisht Savita and Maitra Anirban, Systemic Delivery of Curcumin: 21st Century Solutions for an Ancient Conundrum, Current Drug Discovery Technologies 2009; 6 (3) . https://dx.doi.org/10.2174/157016309789054933
DOI https://dx.doi.org/10.2174/157016309789054933 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CXCR4 and Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Endoglin-Targeted Cancer Therapy
Current Drug Delivery Dual Time F-18 FDG PET/CT Imaging in the Diagnosis of Renal Cell Cancer
Current Medical Imaging Target Identification of Grape Seed Extract in Colorectal Cancer Using Drug Affinity Responsive Target Stability (DARTS) Technique: Role of Endoplasmic Reticulum Stress Response Proteins
Current Cancer Drug Targets Novel Therapeutic Strategies Against Cancer: Marine-derived Drugs May Be the Answer?
Anti-Cancer Agents in Medicinal Chemistry New Approaches With Natural Product Drugs for Overcoming Multidrug Resistance in Cancer
Current Pharmaceutical Design Phase II Drug Metabolism and Individualized Drug Therapy: A Focus on Functional Genetic Variation in UDP-Glucuronosyltransferases
Current Pharmacogenomics and Personalized Medicine Estrogen Catechols Detection as Biomarkers in Schistosomiasis Induced Cancer and Infertility
Letters in Drug Design & Discovery The Production and Role of Gastrin-17 and Gastrin-17-Gly in Gastrointestinal Cancers
Protein & Peptide Letters Vitamin D Metabolites and/or Analogs: Which D for Which Patient?
Current Vascular Pharmacology Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy
Current Drug Metabolism Novel Glitazones with Diverse Peroxisome Proliferator Activated Receptor Modulatory Potential
Current Bioactive Compounds TRPV1 Activation is Not An All-Or-None Event: TRPV1 Partial Agonism/Antagonism and Its Regulatory Modulation
Current Topics in Medicinal Chemistry Pomegranate, its Components, and Modern Deliverable Formulations as Potential Botanicals in the Prevention and Treatment of Various Cancers
Current Drug Delivery Exploring the Role of Phytochemicals as Potent Natural Photosensitizers in Photodynamic Therapy
Anti-Cancer Agents in Medicinal Chemistry Contribution of Platelet-Derived CD40 Ligand to Inflammation, Thrombosis and Neoangiogenesis
Current Medicinal Chemistry Advances in Drug Discovery to Assess Cholinergic Neurotransmission: A Systematic Review
Current Drug Discovery Technologies Down-Regulation of DDR1 Induces Apoptosis and Inhibits EMT through Phosphorylation of Pyk2/MKK7 in DU-145 and Lncap-FGC Prostate Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry miRNA and Proteomic Dysregulation in Non-Small Cell Lung Cancer in Response to Cigarette Smoke
MicroRNA Biosystems Engineering of Prokaryotes with Tumor-Killing Capacities
Current Pharmaceutical Design